000			02239 a2200613 4500
005			20250517212657.0
264		0	_c20190903
008			201909s 0 0 eng d
022			_a1556-1380
024	7		_a10.1016/j.jtho.2018.03.032 _2doi
040			_aNLM _beng _cNLM
100	1		_aFeng, Po-Hao
245	0	0	_aBevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. _h[electronic resource]
260			_bJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _c07 2018
300			_a958-967 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBevacizumab _xadministration & dosage
650	0	4	_aBrain Neoplasms _ximmunology
650	0	4	_aCalgranulin B _xmetabolism
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aErbB Receptors _xgenetics
650	0	4	_aErlotinib Hydrochloride _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aGefitinib _xpharmacology
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aMyeloid-Derived Suppressor Cells _xdrug effects
650	0	4	_aPrognosis
650	0	4	_aSurvival Rate
700	1		_aChen, Kuan-Yuan
700	1		_aHuang, Yu-Chen
700	1		_aLuo, Ching-Shan
700	1		_aWu, Shen Ming
700	1		_aChen, Tzu-Tao
700	1		_aLee, Chun-Nin
700	1		_aYeh, Chi-Tai
700	1		_aChuang, Hsiao-Chi
700	1		_aHan, Chia-Li
700	1		_aLin, Chiou-Feng
700	1		_aLee, Wei-Hwa
700	1		_aKuo, Chih-Hsi
700	1		_aLee, Kang-Yun
773	0		_tJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _gvol. 13 _gno. 7 _gp. 958-967
856	4	0	_uhttps://doi.org/10.1016/j.jtho.2018.03.032 _zAvailable from publisher's website
999			_c28315982 _d28315982